Liraglutide, 0.6 to 1.8 mg per day or Exenatide, 5 to 10 µg twice a day.

Drug: GLP-1 analog

GLP-1 analog treatment

Other Name: Liraglutide, Victoza or Exenatide, Byetta.

Detailed Description:

The objective of this study is to analyse short and medium-term efficacy on clinical, immunological and histopathological parameters of a GLP-1 receptor agonist on moderate to severe psoriasis plaques in a group of patients with type 2 diabetes.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01687582